CTOs on the Move

HealthiVibe

www.healthivibe.com

 
HealthiVibe captures patient insights around clinical trial design and patient-centered initiatives. We believe the patient voice is critical in healthcare.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Dan Kett
Director Information Technology Services Profile

Similar Companies

Hysitron

Hysitron is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ARTMS

ARTMS Inc. is the global leader in the development of novel technologies and products for enabling the cyclotron production of the world’s most-used diagnostic imaging isotopes.

Calvary Healing Center

About Calvary Center: Residential/Inpatient/Full Medical Detox/IOP/PHP Treatment for Alcohol, Drugs and Problem Gambling Calvary Addiction Recovery Centers treatment program is for men and women, 18 years and older, who are struggling with substa...

IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx`s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx`s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions. IntelGenx`s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx`s state-of-the-art manufacturing facility offers full service by providing lab-scale through to pilot- and commercial-scale production.

Promentis Pharmaceuticals

Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.